Trial: 202003096

A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Phase

I/II (Cancer Control)

Principal Investigator

Park, Haeseong

Disease Site

Colon; Corpus Uteri; Lung; Ovary; Pancreas; Rectum

Learn more about this study at: clinicaltrials.gov